DK1511466T3 - Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD - Google Patents

Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD

Info

Publication number
DK1511466T3
DK1511466T3 DK03704789T DK03704789T DK1511466T3 DK 1511466 T3 DK1511466 T3 DK 1511466T3 DK 03704789 T DK03704789 T DK 03704789T DK 03704789 T DK03704789 T DK 03704789T DK 1511466 T3 DK1511466 T3 DK 1511466T3
Authority
DK
Denmark
Prior art keywords
glycosaminoglycans
copd
heparin
treatment
respiratory disorders
Prior art date
Application number
DK03704789T
Other languages
English (en)
Other versions
DK1511466T4 (da
Inventor
Janis Kay Shute
Mary Patricia Carroll
Peter Morey Hockey
Conway Joy H Dr
Original Assignee
Ockham Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27739233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1511466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0203773A external-priority patent/GB0203773D0/en
Priority claimed from GB0203830A external-priority patent/GB0203830D0/en
Priority claimed from GB0211414A external-priority patent/GB0211414D0/en
Priority claimed from GB0224330A external-priority patent/GB0224330D0/en
Application filed by Ockham Biotech Ltd filed Critical Ockham Biotech Ltd
Application granted granted Critical
Publication of DK1511466T3 publication Critical patent/DK1511466T3/da
Publication of DK1511466T4 publication Critical patent/DK1511466T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DK03704789.1T 2002-02-18 2003-02-14 Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD DK1511466T4 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0203773A GB0203773D0 (en) 2002-02-18 2002-02-18 Improving drug delivery to the respiratory tract
GB0203830A GB0203830D0 (en) 2002-02-18 2002-02-18 Improving drug delivery to the respiratory tract
GB0211414A GB0211414D0 (en) 2002-05-17 2002-05-17 Treatment of respiratory disorders
GB0224330A GB0224330D0 (en) 2002-10-18 2002-10-18 Treatment of respiratory disorders
PCT/GB2003/000663 WO2003068187A1 (en) 2002-02-18 2003-02-14 Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd

Publications (2)

Publication Number Publication Date
DK1511466T3 true DK1511466T3 (da) 2009-02-16
DK1511466T4 DK1511466T4 (da) 2015-03-30

Family

ID=27739233

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03704789.1T DK1511466T4 (da) 2002-02-18 2003-02-14 Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD

Country Status (10)

Country Link
EP (1) EP1511466B2 (da)
AT (1) ATE410147T1 (da)
AU (1) AU2003207317A1 (da)
CA (1) CA2516318C (da)
DE (1) DE60323973D1 (da)
DK (1) DK1511466T4 (da)
ES (1) ES2315479T5 (da)
HK (1) HK1074582A1 (da)
PT (1) PT1511466E (da)
WO (1) WO2003068187A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005032483A2 (en) 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
TW201306847A (zh) * 2010-11-30 2013-02-16 Vectura Ltd 組成物及用途
WO2012129237A2 (en) * 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
EP3737364A1 (en) 2018-01-11 2020-11-18 Emphysema Solutions BV Compositions and methods for the treatment of lung emphysema and other forms of copd
IT202100021602A1 (it) * 2021-08-09 2023-02-09 Sofar Spa Composizione in forma di polvere secca per inalazione per uso in un metodo di trattamento di un’infiammazione e/o di uno stress ossidativo dell’apparato respiratorio causata/o da inquinamento dell’aria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
WO2002032406A2 (en) * 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides

Also Published As

Publication number Publication date
DK1511466T4 (da) 2015-03-30
CA2516318A1 (en) 2003-08-21
DE60323973D1 (de) 2008-11-20
ES2315479T5 (es) 2015-07-01
AU2003207317A1 (en) 2003-09-04
CA2516318C (en) 2011-07-19
HK1074582A1 (en) 2005-11-18
EP1511466A1 (en) 2005-03-09
EP1511466B2 (en) 2015-02-25
ES2315479T3 (es) 2009-04-01
PT1511466E (pt) 2009-01-16
WO2003068187A1 (en) 2003-08-21
EP1511466B1 (en) 2008-10-08
ATE410147T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
HK1074582A1 (en) Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
NL300933I2 (nl) Letermovir
SE0301010D0 (sv) Novel compounds
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
SE0301009D0 (sv) Novel compounds
SE0202241D0 (sv) Novel Compounds
RS20050361A (en) Novel medicament for the treatment of chronic obstructive pulmonary diseases
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EA200600223A1 (ru) Замещённый 2-аминотетралины для лечения депрессии
MY139498A (en) Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
WO2020217116A3 (en) Long acting inhalation compositions of indacaterol
ATE380188T1 (de) Substituierte chinolone
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
DK1610787T3 (da) Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme
EA200100906A1 (ru) Композиция контролируемого высвобождения для лечения copd хронического обструктивного заболевания легких
SE9900834D0 (sv) Novel combination
TW200508206A (en) Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid, and medicament containing them
ATE553088T1 (de) Substituierte chinolone ii
NO20056089L (no) Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner
EA200601853A1 (ru) Лечение нарушенной дыхательной функции
TW200507837A (en) N-substituted (benzoimidazol-2-yl)phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
NO20060229L (no) Gaboxadol for behandling av depresjon og andre affektive lidelser
UA92908C2 (ru) Соединения, производные от 5-тиоксилозы, и их терапевтическое применение